PDFファイル
Contents
1. alli af SERED EE ah m ADVIA Centaur ADVIA Centa2. 1 30 pL dead volume 2 BITE 1500
3. 5 LD 3 cal
4. m 2015 1 4 2013 4 3 ADVIA Centaur ADVIA Centaur 1 EDTA RFE IC He CLSI Clinical and Laboratory Standards Institute 1
5. L HPLC MS 5 M 20 MO HA ABR
6. 6 Oo 2 8 2 8 C C7 7 20 1 1 2 4 2 8C 24
7. FPIA 3 EIA 1 Deming TREE BHR BARAS KE 108 1 11 0 962 75 1 04 5 0 967 67 0 89 20 0 966 250 1 03 0 963 wk 1 97 0 88 14 0 963 2 105 1 05 15 0 978 3 48 1 14 35 0 958 250 1 03 0 963 FPIA 1 97 0 76 10 0 967 2 97 0 67 2 0 987 3 48 0 73 9 0 968 242 0 72 4 0 970 EIA 1 219 0 68 18 0 960 HM 182 1 02 8 0 909 68 1 15 104 0 898 250 1 03 0 963 1600 1400 e E mo D 8 1000 N ia 44 800 K 600 400 8A MSR ow pat l s Z Deming 200 1 08 1 03x 04 T T T T T T 200 400 600 800 1000 1200 1400 1600
8. 10 5 EB FK506 100 100 100 100 1000 100 100 5 100 N 100 100 200 100 100 G 100 100 V 100 100 150 100 PEERY 100 100 100 120 100 230 100 250 100 100 100 100 100 100 100 VEY REI 100 100 100 500 EDTA 2924 100
9. 13A2X10031000008 m m 1 5 0 mL 12 5 mL
10. 1 400pL 2 aa T 3 100 pL 4 10 5 ADVIA Centaur VREK
11. 2 8C 2 8 i 2 8 C 21 2 8 C 4 21
12. m 1 C1 2 8 2 4 25 C CRE 2 1 2 2 1 6 50 04564446 1 IED KICI WAAC ARH 5000 1500 mLIA 03852677 ADVIA CentaurIXPIXPT 112219 1000 300 mL 00497043 ADVIA Centaur CP 04567127 2 26 mL 04567682 2 1 2x2500 mL ADVIA Centaur XP XPT CP JH 03773025 2X1500 mL ADVIA Centaur XP XPTICP JH 01137199 112351 12 04786546 120 0 mL B 1 10 11 12 13 Potter JM and Self H Cyclosporine A Variation in whole blood levels related to in vitro anticoa
13. 1 lt 0 1 12 1 2 ADVIA Centaur CP 1 3 42 28 ADVIA Centaur CP 14 H 2 WEG 28 ADVIA Centaur CP 14 H
14. alle HIV HBV HCV pH lt 2 pH13 1 2
15. 1 5 2 5 Ni ng mL CV CV 1 1490 03 1 8 Del 2 1385 23 1 1 4 8 ADVIA Centaur CP 4 2 2 20 4 20 n 160 DEL ng mL CV CV CV 1 75 31 4 2 5 3 6 8 2 188 81 3 1 4 3 5 3 3 414 36 3 3 5 1 6 1 4 823 48 2 9 6 9 7 5 20 9 30 nglmL USP m
16. OT m 1 3 ADVIA Centaur XP XPT 30 1500 ng mL 30 ng mL C1500 ngjmlt 1 High Low Low High High 2 25 10 6 CF 30 3 CV 15 2 g 3
17. 2 2 ADVIA Centaur 91 108 96 5 ADVIA Centaur XP XPT 5 3 2 3 5 nm 150 ng mL CV CV 1 84 7 1 75 2 177 Bl 5 6 3 348 5 4 5 5 4 615 6 1 6 7 5 1138 5 9 7 7 1 171 4 5 5 3 2 291 5 4 5 8 3 482 4 9 5 7 CLSI EP5 A23 5 1 2 1 2 20 3 n 120 ng mL CV CV 1 85 3 8 5 7 2 181 2 9 4 1 3 372 2 8 5 5 4 639 4 1 6 7 5 1023 4 6 9 0 2 1
18. 5 0 mL CsA 2 1500 mL 0 5 0 1N 1500 mL 0 25N ADVIA Centaur CP 300mL m m ri enti B F
19. ngimL 500 y 0 e 400 8 4 95 8 w 156 2 172 9 ji T T T T T T T 1 9 200 400 600 800 1000 1200 1400 1600 ADVIA Centaur CP 30 71 1476 1 ng7mL EDTA 370 ADVIA Centaur CP ADVIA Centaur CP ADVIA Centaur ADVIA Centaur ADVIA Centaur CP 0 97 ADVIA Centaur 19 38 ng mL r 0 989 4 ADVIA Centaur XP XPT 191 1478 ngmL 5 12 2 4 8 90 7 108 5 97 49 ADVIA Centaur CP 413 21 1062 9 nglmLOt AMS RAZ 7 12 2 4 8 100 7 119 8 108 4 Lice
20. 200 250 100 100 100 100 120 500 100 630 B 100 100 CLSI EP7 A23 ADVIA Centaur 200 ngjmL 1000 nglmL AM1 AM1c AM4N AM9 AM19 2A 8 Ko AM1 1000 lt 5 AM1c 1000 lt 5 AM4N 1000 lt 5 AM19 1000 lt 5 AM9 1000 15 0 m 1 1 2 42
21. 1 2 25 1 12 2 8C 21 3 1 000ppm 1 2 1 210 20 Microprotect
22. 2 3 i 10 ADVIA Centaur RA 60 mg dL AUE 40 mg dL 900 mg dL 300 mg dL 20 mg dL 8 gldL 12 gdL y 100 nglml 12 3 58 6 200 ng mL
23. gulant usage Ther Drug Monit 1986 8 122 125 Clinical and Laboratory Standards Institute formerly NCCLS Proce dures for the Handling and Processing of Blood Specimens Approved Guide line Third Edition Wayne PA Clinical and Laboratory Standards Institute 2004 NCCLS Document H18 A3 Clinical and Laboratory Standards Institute formerly NCCLS Inter ference Testing in Clinical Chemistry Approved Guideline Second Edition Wayne PA Clinical and Laboratory Standards Institute 2005 NCCLS document EP7 A2 Boscato LM Stuart MC Heterophilic antibodies a problem for all immunoassays Clin Chem 1988 34 27 33 Food and Drug Administration Class II Special Controls Guidance Document Cyclosporine and Tacrolimus Assays Guidance for Industry and FDA 2002 Dunn CJ Wagstaff AJ Perry CM Plosker GL and Goa KL Cyclospo rine Drugs 2001 25 1957 2016 Kahan BD Shaw LM Holt D Grevel J and Johnston A Consensus Document Hawk s Cay Meeting on Therapeutic Drug Monitoring of Cyclosporine Clin Chem 1990 36 8 1510 1516 Kahan BD Keown P Levy GA Johnston A Therapeutic drug monitor ing of immunosuppressant drugs in clinical practice Clin Ther 2002 24 330 350 Wong SH Therapeutic drug monitoring for immunosuppressants Clin Chim Acta 2001 313 241 253 Soldin SJ Steele BW Witte DL Wang E and Elin RJ Lack of specificity of cyclosporine immunoassays Arch Pathol Lab Med 2003 127 19 22 Hamwi A Sal
24. ng mL 5 12 L Dilution factor Su 10 xl 2 RE 2
25. omon A Steinbrugger R Fritzer Szekeres M Jager W and Szekeres T Cvclosporine metabolism in patients after kidnev bone marrow heart lung and liver transplantation in the earlv and late posttransplant periods Am J Clin Pathol 2000 114 536 543 Oellrich M Armstrong VW Schutz E and Shaw LM Therapeutic drug monitoring of cyclosporine and tacrolimus Clinical Biochemistry 1998 31 309 316 Clinical and Laboratory Standards Institute formerly NCCLS Evalu ation of Precision Performance of Quantitative Measurement Methods Approved Guideline Second Edition Wayne PA Clinical and Laboratory Standards Institute 2004 NCCLS Document EP5 A2 jg 03 3493 8400 Ml 1 11 1 ADVIA Centaur ACS 180 Siemens 10335448M1_03 ADVIA Centaur 10629836_EN RevJ CP 10629958 Rev G
26. ur XP ADVIA Centaur XPT ADVIA Centaur CP 30pL NZ 37 C 4 73 100 pL 37 C 2 53 NI 37 C 3 03 100 L 37 C 2 5 NI 37 C 3 03 250puL 370 2 5 370 3 0 Vv BF 1 NL 300 pL 300 u L Vv B Bbound F free RLUs 1 ng mL nmolL SI 1 ng mL 0 8315 nmolL
Download Pdf Manuals
Related Search